SEEG Investigation of Mood Dysregulation in Epilepsy
SEEG Investigation of Mood Dysregulation in People With Epilepsy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundation Center for Behavioral Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects will be a part of the epilepsy-monitoring unit for long-term SEEG recordings and analysis
Exclusion Criteria:
- Subjects that experience surgical complications during the implant procedure will be excluded from the study
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Epilepsy Subjects
Subjects will be recruited from the epilepsy-monitoring unit.
These subjects would have been already assessed by the Epilepsy Center at the Cleveland Clinic for surgical treatment of medically refractory epilepsy and would have already had SEEG electrodes placed in cortical and limbic areas for clinical diagnostic purposes.
|
To directly record brain activity from the frontal-limbic circuitry of subjects in the resting state and while they engage in behavioral tasks designed to assess emotional response to negative stimuli and different aspects of impulse control and emotional processing
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Emotional Face Task and Emotional Go-No Go Task
Time Frame: 2 years
|
To use face pictures depicting negative, positive and neutral emotions this task measures brain area activation abnormalities while responding and inhibiting responses to positive and negative emotions.
|
2 years
|
|
Maintaining and suppressing emotions
Time Frame: 2 years
|
To use the International Affective Picture System, subjects will be asked to either maintain or suppress their emotions.
|
2 years
|
|
Resting state cortico-limbic brain connectivity
Time Frame: 2 years
|
Resting state recordings will be collected from the cortical areas - prefrontal cortex, orbitofrontal cortex and anterior and posterior cingulate cortex as well as limbic areas - amygdala and hippocampus
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 15-1007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NCT03860298CompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant Epilepsy
-
NCT03916848Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, Focal
-
NCT06153186TerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence Epilepsy
-
NCT06310954RecruitingEpilepsy Intractable | Epilepsy in Children
-
NCT01311440CompletedEpilepsy | Generalized Epilepsy | Focal Epilepsy
-
NCT00150813CompletedEpilepsy, Tonic-clonic
-
NCT00150787CompletedEpilepsy, Tonic-clonic
-
NCT06602570Not yet recruitingEpilepsy Intractable | Epilepsy in Children
-
NCT03278210CompletedFocal Epilepsy | Epilepsy Intractable
-
NCT04569708CompletedEpilepsy | Epilepsy; Seizure | Rolandic Epilepsy | Rolandic Epilepsy, Benign | Centrotemporal Epilepsy | Centrotemporal; EEG Spikes, Epilepsy of Childhood
Clinical Trials on SEEG Recordings
-
NCT06524479RecruitingSleep | Refractory Epilepsy
-
NCT07305311Not yet recruitingRefractory Epilepsy | Neuromodulation
-
NCT03644732RecruitingFocal Epilepsy | Refractory Epilepsy
-
NCT02844374Unknown
-
NCT05997758RecruitingHealthy | Drug Resistant Epilepsy
-
NCT03916848Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, Focal
-
NCT04096651CompletedProgressive Supranuclear Palsy
-
NCT05023694Completed